Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs Lithium Americas Corp (LAC) Price & Performance

Davita IncTrade
Lithium Americas CorpTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs Lithium Americas Corp — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Lithium Americas Corp trades at $2.39 (market cap $876.06M). The key difference: Davita Inc is far larger — about 12.9× Lithium Americas Corp's market cap, and Davita Inc is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Lithium Americas Corp for 27 Days on average.

DVALAC
Market Cap
$11.28B$876.06M
Volume
650,2949,397,178
Sector
HealthBasic Materials
52-Week High
$240.96$10.05
52-Week Low
$103.87$2.36
Typical Hold Time
113 Days27 Days
Enterprise Value
$24.00B$1.21B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.

The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.

Lithium Americas Corp

Lithium Americas (LAC) trades at $2.41, down 5.12% on the day, reflecting ongoing market pressure despite recent earnings beats. The stock shows mixed signals with bearish technical indicators but bullish analyst sentiment, with 7 buy ratings and a $4.00 consensus price target. The company remains in development phase with no current revenue, reporting negative EBITDA of $51.80M for 2025, but has secured substantial financing to advance its Thacker Pass lithium project.

LAC presents a high-risk, high-reward opportunity as it transitions from development to execution. The primary catalyst is successful commercialization of Thacker Pass, which could drive significant rerating, but investors face substantial execution risk, lithium price volatility, and continued cash burn until production begins. Analyst optimism contrasts with current financial performance, creating a speculative investment case.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DVA
91% Buy9% Sell
Avg holding period · 113 Days
LAC
54% Buy46% Sell
Avg holding period · 27 Days

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA →

About Lithium Americas Corp

Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.

Read more on LAC →